Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant

Developing a first-void urine-based infection model to study HPV-specific antibody-virion interaction before and after vaccination with the Gardasil-9 HPV vaccine – a non-randomized open-label study.

A Registry-Based Extension of Protocol V503-001 in Countries with Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women.

VAC-WARTS Efficacy of the nonavalent HPV vaccine in the treatment of difficult-to-treat palmo-plantar warts

CONDYVAC. Efficacy study of the quadrivalent Human Papilloma Virus (HPV) vaccine to prevent recurrence of External Genital Warts (EGW) in patients who were cured in the first place

Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)

A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV16/18-Positive Women Before and After Vaccination with 9vHPV, a Multivalent L1 Virus-like Particle Vaccine, Evaluated in Cervical, Anal, Vulvar, Urine and Oral Samples Obtained After One, Two, and Three Vaccine Doses (RIFT-HPV1/RIFT-HPV2).

Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden